Albuterol sulfate inhalation efficacy
Pro Research Analysisby 
Searched over 200M research papers
Albuterol Sulfate Inhalation Efficacy in Asthma and COPD
Efficacy in Asthma: Metered-Dose Inhalers (MDI) vs. Dry Powder Inhalers (DPI)
Multiple studies show that albuterol sulfate delivered via both metered-dose inhalers (MDI) and dry powder inhalers (DPI) is effective in improving lung function in patients with mild to moderate asthma. Both delivery methods result in similar improvements in forced expiratory volume in one second (FEV1), and both are significantly more effective than placebo. There are no significant differences in safety or adverse events between the two inhaler types, making them equally suitable for asthma management 110.
Albuterol Sulfate with New Propellants
Albuterol sulfate formulated with the non-chlorofluorocarbon (CFC) propellant HFA-134a provides bronchodilation and safety profiles comparable to traditional CFC-based albuterol inhalers. This means that the transition to environmentally friendly propellants does not compromise the drug’s effectiveness or safety for asthma patients .
Dose-Response and New Delivery Technologies
Recent studies comparing new co-suspension delivery technology for albuterol sulfate MDI with standard Proventil® show equivalent bronchodilation effects. Both 90 µg and 180 µg doses of the new MDI and Proventil® are significantly better than placebo, and no new safety concerns were identified. This supports the use of these new inhalers in clinical practice .
Efficacy in Infants and Children
In infants under two years old with acute obstructive airway disease, albuterol sulfate delivered via MDI with a spacer and face mask is both safe and effective. Both 180 µg and 360 µg doses led to significant improvement in asthma symptom scores, with no major safety issues observed .
Combination Therapy: Albuterol with Budesonide or Theophylline
Combining albuterol sulfate with budesonide (an inhaled corticosteroid) in acute asthma leads to faster symptom relief and greater clinical improvement compared to albuterol alone, with no increase in adverse reactions . Similarly, in elderly patients with acute asthma, combining albuterol sulfate inhalation with oral theophylline tablets results in better lung function and higher response rates than albuterol alone, with good safety and tolerance 57.
Efficacy in COPD: Albuterol Alone vs. Combination with Ipratropium
For patients with chronic obstructive pulmonary disease (COPD), combining albuterol sulfate with ipratropium bromide provides better bronchodilation and improved lung function than albuterol alone. This combination does not increase the risk of side effects and is more effective for long-term management of COPD symptoms 68.
Conclusion
Albuterol sulfate inhalation is highly effective for improving lung function and relieving symptoms in asthma and COPD across various age groups and delivery methods. Both MDI and DPI forms are equally effective, and new propellant technologies maintain efficacy and safety. Combination therapies with budesonide, theophylline, or ipratropium can further enhance clinical outcomes, especially in acute or severe cases, without increasing adverse effects.
Sources and full results
Most relevant research papers on this topic
Clinical Observation of Aerosol Inhalation of Albuterol Sulfate and Budesonide in the Treatment of Acute Asthma
Aerosol inhalation of albuterol sulfate and budesonide effectively improves symptoms and shortens the duration of acute asthma treatment without adverse drug reactions.
Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma.
HFA-134a albuterol sulfate provides bronchodilation comparable to CFC albuterol and has a similar safety profile in patients with asthma.
DOI
Repeat Dosing of Albuterol via Metered-Dose Inhaler in Infants With Acute Obstructive Airway Disease: A Randomized Controlled Safety Trial
Repeated dosing of albuterol HFA 180 or 360 mg via metered-dose inhaler in infants with acute obstructive airway disease showed no significant safety issues and improved symptoms by at least 48%.
Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials
AS MDI 180 g is an equivalent dose to Proventil for bronchodilation in patients with asthma, supporting its selection for Phase III clinical trials.
Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma.
The breath-actuated inhaler (Spiros) is therapeutically comparable to the conventional metered dose inhaler (Ventolin) for providing one and two actuations of albuterol in patients with mild-to-moderate asthma.
DOI